Ariel Sponsors PancreasFest 2022

Share on facebook
Share on twitter
Share on linkedin
Share on email
PancreasFest 2022

PITTSBURGH, Pa., July 22, 2022

Ariel Precision Medicine was a sponsor of PancreasFest 2022,  an annual forum where pancreatic leaders from across the world come together to discuss pancreatitis, CFTR- related diseases and pancreatic cancer research, discoveries and opportunities for improvement.

Ariel experts hosted two poster sessions and a breakout session featuring their latest product and research developments in the areas of pancreatic disease diagnosis and management. 

During this year’s event, the Ariel team met with customers, partners and collaborators to share product updates and present new data about the discoveries made at the company in recent months. “The event is a unique opportunity for Ariel to establish new multidisciplinary collaborations with the world’s key stakeholders to advance discoveries in pancreatitis and pancreatic cancer,” said Jessica Gibson, Co-Founder and CEO.

“Ariel has taken a bold approach in creating new solutions and technologies to improve the mechanistic diagnosis and develop treatments for serious pancreatic disease,” added Gibson. “It’s events like these that open up the doors for further collaboration and communication in our field, and we look forward to it every year!”

David C. Whitcomb MD PhD, Ariel’s Chief Scientific Officer and Co-Founder,  is co-director of PancreasFest.

PancreasFest 2022
Darwin Conwell, MD, MS was an award honoree, pictured with Dr. Whitcomb.

Featured Speaker

David C. Whitcomb, MD, PhD Co-Founder and Chief Scientific Officer, Ariel Precision Medicine

David C Whitcomb MD PhD Professor of Medicine, University of Pittsburgh

Topic: Multi-organ Failure and Mechanisms of Acute Pancreatitis

Dr. Whitcomb is a pioneer in the use of mathematics, genetics, genomics, cell biology, neurosciences, immunology and epidemiology to study complex inflammatory disorders and cancer risks of the digestive system. He co-founded Ariel Precision Medicine along with Jessica M. Gibson in 2015.

As Chief Scientific Officer with Ariel, Dr. Whitcomb utilizes his experience and insights as a physician, scientist and innovator to oversee the scientific and translational functions of the company.

With over 25 years of continuous NIH funding, he has built one of the top human genetics programs for complex digestive diseases. He has published over 400 papers, reviews and book chapters with > 35,000 citations, an h-index of over 90 and i10index of over 300.

Related Articles